Clinical Experience with Moxifloxacin in Patients with Respiratory Tract Infections

Annals of Pharmacotherapy

Volumn 38, Issue 5, 2004, Pages 749-754

  Faich, Gerald A ^a   Morganroth, Joel ^b,c   Whitehouse, Alan B ^d,e   Brar, Jugroop S ^f   Arcuri, Peter ^g   Kowalsky, Steven F ^h   Haverstock, Daniel C ⁱ   Celesk, Roger A ⁱ   Church, Deborah A ⁱ  

^a Pharmaceutical Safety Assessments Inc   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c EResearch Technology Inc   (United States)

^d University Hospital Augusta   (United States)

^e MEDICAL COLLEGE OF GEORGIA   (United States)

^f Saratoga Emergency Physicians   (United States)

^g Bayer Pharmaceuticals Corporation ^*

^h BAYER CORPORATION   (United States)

ⁱ Bayer Pharmaceuticals Corporation   (United States)

Author keywords

Bronchitis; Moxifloxacin; Pneumonia; Safety; Sinusitis

Indexed keywords

MOXIFLOXACIN; THEOPHYLLINE;

ABDOMINAL PAIN; ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANOREXIA; ARTICLE; CHILD; CHRONIC BRONCHITIS; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; DYSPNEA; FEMALE; FEVER; HEADACHE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART PALPITATION; HUMAN; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RASH; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; RISK; SINUSITIS; SYNCOPE; THORAX PAIN; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; QUINOLINES; RESPIRATORY TRACT INFECTIONS;

EID: 1942534978     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C066     Document Type: Article

References (21)

1. Gwaltney JM Jr. Acute community-acquired sinusitis. Clin Infect Dis 1996;23:1209-23.
2. Reynolds HY. Chronic bronchitis and acute infectious exacerbations. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995:608-12.
3. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995;333:1618-24.
4. Jorgensen JH, Doern GV, Maher LA, Howell AW, Redding JS. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 1990;34:2075-80.
5. Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez M, Jones RN. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001;32(suppl 2):S81-93.
6. Doern GV, Heilmann KP, Huynh HK, Rhomberg PR, Coffman SL, Brueggemann AB. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 2001;45:1721-9.
7. Package insert. Avelox (moxifloxacin). West Haven, CT: Bayer Pharmaceuticals, March 2003.
8. Jaillon P, Morganroth J, Brumpt I, Talbot G. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group. J Antimicrob Chemother 1996;37(suppl A): 161-7.
9. Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B. Torsades de pointe probably related to sparfloxacin (letter). Eur J Clin Microbiol Infect Dis 1996;15:350-1.
10. Ball P. Quinolone-induced QT interval prolongation: a not-so-unexpected class effect. J Antimicrob Chemother 2000;45:557-9.
11. FDC Report. FDA/PhRMA task force to assess QT risk by pre-clinical markers. The Pink Sheet - Prescription Pharmaceuticals and Biotechnology 1999;61:15-6.
12. Committee for Proprietary Medicinal Products (CPMP), the European Agency for the Evaluation of Medicinal Products. Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. London: CPMP, December 17, 1997.
13. Morganroth J, Brown AM, Critz S, Crumb WJ, Kunze DL, Lacerda AE, et al. Variability of the QTc interval: impact on defining drug effect and low-frequency cardiac event. Am J Cardiol 1993;72:26B-31B.
14. Oberg KC, Bauman JL. QT interval prolongation and torsades de pointes due to erythromycin lactobionate. Pharmacotherapy 1995;15:687-92.
15. Iannini PB. Quinolone-induced QT interval prolongation: a not-so-unexpected class effect (letter). J Antimicrob Chemother 2001;47:893-4.
16. Church D, Haverstock D, Andriole V. Moxifloxacin: a review of its safety profile based on worldwide clinical trials. Today's Therapeutic Trends 2000;18:205-33.
17. Package insert. Tequin (gatifloxacin). Princetown, NJ: Bristol-Myers Squibb, July 2003.
18. Package insert. Levaquin (levofloxacin) tablets. Raritan, NJ: Ortho-McNeil Pharmaceutical, June 2003.
19. Food and Drug Administration. COSTART (Coding Symbols for Thesaurus of Adverse Reaction Terms). Washington, DC: Department of Health and Human Services, 1995.
20. Package insert. Augmentin (amoxicillin/clavulanate) tablets. Research Triangle Park, NC: GlaxoSmithKline, May 2002.
21. Package insert. Zithromax (azithromycin) tablets/oral suspension. New York: Pfizer, October 2002.